{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:44:43Z","timestamp":1773326683995,"version":"3.50.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1245\/s10434-020-09167-1","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T17:03:13Z","timestamp":1601312593000},"page":"940-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant Chemotherapy in Resectable Gallbladder Cancer is Underutilized Despite Benefits in Node-Positive Patients"],"prefix":"10.1245","volume":"27","author":[{"given":"Yi-Lei","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"9167_CR1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08973-x","author":"PM Kemp Bohan","year":"2020","unstructured":"Kemp Bohan PM, Kirby DT, Chick RC, et al. Adjuvant chemotherapy in resectable gallbladder cancer is underutilized despite benefits in node-positive patients. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08973-x.","journal-title":"Ann Surg Oncol"},{"key":"9167_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"key":"9167_CR3","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","volume":"28","author":"A Sharma","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28:4581\u20136. https:\/\/doi.org\/10.1200\/JCO.2010.29.3605.","journal-title":"J Clin Oncol"},{"key":"9167_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.hpb.2017.05.010","volume":"19","author":"M Ghidini","year":"2017","unstructured":"Ghidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB. 2017;19:741\u20138. https:\/\/doi.org\/10.1016\/j.hpb.2017.05.010.","journal-title":"HPB"},{"key":"9167_CR5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/jco.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37:658\u201367. https:\/\/doi.org\/10.1200\/jco.18.00050.","journal-title":"J Clin Oncol"},{"key":"9167_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.hpb.2020.02.001","volume":"22","author":"WJ Ma","year":"2020","unstructured":"Ma WJ, Jin YW, Wu ZR, et al. Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers. HPB. 2020;22:939\u201349. https:\/\/doi.org\/10.1016\/j.hpb.2020.02.001.","journal-title":"HPB"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09167-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09167-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09167-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T23:34:28Z","timestamp":1632785668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09167-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":6,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9167"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09167-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}